[1] Russell RG. Bisphosphonates: the first 40 years [J]. Bone, 2011, 49(1)∶2-19 [2] Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate induced exposed bone (osteonecrosis/osteoporosis) of the jaws: risk factors, recognition, prevention and treatment [J]. J Oral Maxillofac Surg,2005,63(11)∶1567-1575 [3] Kalra S, Jain V. Dental complications and management of patients on bisphosphonate therapy: A review article [J]. Oral Biol Craniofac Res,2013,3(1)∶25-30 [4] 李阳,高永波.种植术后双膦酸盐相关性颌骨坏死处理体会[J].口腔颌面外科杂志,2016,26(6)∶427-430 [5] Dwan K, Phillipi CA, Steiner RD, et al. Bisphosphonate therapy for osteogenesis imperfecta [J]. Cochrane Database Syst Rev, 2014,(7):CD005088 [6] Fleisch H. Biphosphonate as a therapeutic drug-experimental studies and clinical application [J]. Ther Umsch,1985, 42(6)∶366-375 [7] Wypij JM, HellerDA. Pamidronate disodium for palliative therapy of feline bone-invasive tumors [J]. Vet Med Int,2004,2014∶675172 [8] Bittner T, Lorbeer N, Reuther T, et al. Hemimandibulectomy after bisphosphonate treatment for complex regional pain syndrome: A case report and review on the prevention and treatment of bisphosphonate-related osteone crosis of the jaw [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2012,113(1)∶41-47 [9] Russell RGG, Xia Z, Dunford JE, et al. Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy [J]. Ann N Y Acad Sci,2007,1117(1)∶209-257 [10] Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption [J]. Adv Drug Deliv Rev,2000,42(3)∶175-179 [11] King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates [J]. Pharmacotherapy, 2008, 28(5):667-677 [12] 徐佑兰,邹海啸,李晶.颌骨放射性骨坏死相关危险因素分析[J].口腔医学研究,2014,30(6)∶563-565 [13] Qamheya AHA, Yeniyol S, Arisan V. Bisphosphonate-related osteonecrosis of the jaw and dental implants [J]. J Istanb Univ Fac Dent,2016,50(1)∶59-64 [14] Soucacos PN, Kokkalis ZT, Piagkou M, et al. Vascularized bone grafts for the management of skeletal defects in orthopaedic trauma and reconstructive surgery [J]. Injury,2013,44(Suppl 1)∶S70-S75 [15] Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis [J]. Endocrinol Metab Clin North Am, 2012, 41(3)∶595-611 [16] 王根林,杨惠林,朱雪松,等.骨质疏松性椎体骨坏死的诊断及椎体后凸成形术治疗[J].中国脊柱脊髓杂志,2013,23(3)∶228-232 [17] 童培建,吴云刚,肖鲁伟,等.高凝、低纤和高脂血症在实验性激素性股骨头坏死发生中的作用[J].中国骨伤,2002,15(6)∶343-346 [18] Harrell DB, Caradonna E, Mazzucco L, et al. Non-hematopoietic essential functions of bone marrow cells: a review of scientific and clinical literature and rationale for treating bone defects [J]. Orthop Rev (Pavia),2015,7(4)∶5691 [19] Langdahl B, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis [J]. Ther Adv Musculoskelet Dis,2016,8(6)∶225-235 [20] Haraguchi R, Kitazawa R, Mori K, et al. sFRP4-dependent Wnt signal modulation is critical for bone remodeling during postnatal development and age-related bone loss [J]. Sci Rep,2016,6∶25198 [21] Kim DS, Kim JH, Ohe JY, et al. Bisphosphonate-related osteonecrosis of the jaw in a patient with osteoporosis following treatment of testicular cancer: a case report [J]. J Korean Assoc Oral Maxillofac Surg,2015,41(6)∶327-331 [22] Kim HJ, Park TJ, Ahn KM. Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases [J]. Maxillofac Plast Reconstr Surg,2016,38(1)∶6 [23] Benhamou CL. Effects of osteoporosis medications on bone quality [J]. Joint Bone Spine,2007,74(1)∶39-47 [24] Saia G, Blandamura S, Bettini G, et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction [J]. J Oral Maxillofac Surg,2010,68(4)∶797-804 [25] Saldanha S, Shenoy VK, Eachampati P, et al. Dental implications of bisphosphonate-related osteonecrosis [J]. Gerodontology,2012,29(3)∶177-187 [26] Gao SY, Zheng GS, Wang L, et al. Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB [J]. PLoS One,2017,12(6)∶e0179248 [27] Hoefert S,Sade HC,Munz A,et al.Effect of bisphosphonates on macrophagic THP-1 cell survival in bisphosphonate-related osteonecrosis of the jaw (BRONJ) [J]. Oral Surg Oral Med Oral Pathol Oral Radiol,2016,121(3)∶222 [28] Toulis KA, Anastasilakis AD. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab [J]. Osteoporos Int,2010,21(11)∶1963-1964 [29] Endo Y, Kumamoto H, Nakamura M, et al. Underlying mechanisms and therapeutic strategies for bisphosphonate-related osteonecrosis of the Jaw (BRONJ) [J]. Biol Pharm Bull,2017,40(6)∶739-750 [30] 马泽云,王衣祥.建立大鼠双膦酸盐相关颌骨骨坏死模型并初步分析其发病原因[J].北京大学学报(医学版),2014,46(6)∶945-949 [31] Xu Y, Sun J, Yang X, et al. Pamidronate disodium leads to bone necrosis via suppression of Wnt/β-catenin signaling in human bone marrow mesenchymal stem cells in vitro [J]. J Oral Maxillofac Surg,2017,75(10)∶2135-2143 [32] Woo SB, Hell Stein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaw [J]. Ann Intern Med,2008, 109(6)∶367-373 |